Clinical Trials Logo
  1. Home
  2. Ataxia Telangiectasia
  3. NCT04870866

NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia

Ataxia Telangiectasia Clinical Trial

Official title:
NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia

Clinical Trial Summary

The study investigates the effect of dietary supplementation of nicotinamide ribonucleoside (NR) in children with ataxia telangiectasia (AT), with main focus on neurological symptoms.

Clinical Trial Description

Ataxia Telangiectasia (AT) is a genetic disease, where patients are born with mutations in the Ataxia- Telangiectasia Mutated (ATM) gene. The gene codes for the ATM kinase, which is required for repair of DNA double-stranded breaks and DNA damage response signalling. There is no treatment available for the neurological manifestations of AT. The study investigates the effects of NR (300 mg/day) during 2 years. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04870866
Study type Interventional
Source University Hospital, Akershus
Contact
Status Active, not recruiting
Phase Phase 2
Start date June 5, 2019
Completion date June 16, 2027
View Details
See also
  Status Clinical Trial Phase
Completed NCT02345135 - Susceptibility to Infections in Ataxia Telangiectasia N/A
Active, not recruiting NCT04991701 - A National Retrospective Population Based Cohort Study of the Natural History of Ataxia Telangiectasia
Active, not recruiting NCT05531890 - Comparative Bioavailability of Betamethasone Oral Solution Metered Spray (GTX-102) in Healthy Subjects Phase 1
Recruiting NCT05692596 - The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
Completed NCT05252819 - Whole Body MRI for Cancer Surveillance in A-T
Recruiting NCT03357978 - Susceptibility to Infections, Tumor Risk and Liver Disease in Patients With Ataxia Telangiectasia N/A
Withdrawn NCT02309632 - Pancreatic Cancer Screening of High-Risk Individuals in Arkansas N/A
Not yet recruiting NCT06324877 - Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside N/A
Not yet recruiting NCT01075438 - Immunogenicity of Pneumococcal Vaccines in Ataxia-telangiectasia Patients N/A
Completed NCT03962114 - Effects of Vitamin B3 in Patients With Ataxia Telangiectasia Phase 2
Completed NCT04513002 - Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With a Novel Form of Anaplerosis Phase 2
Completed NCT05471310 - Videoocular Assessment of Eye Movement Activity in an Ataxia Telangiectasia
Recruiting NCT06193200 - To Evaluate the Effects of EryDex in Patients With A-T Phase 3
Recruiting NCT03563053 - Open-label, Long-term, Extension Treatment Using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients With Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study Phase 3
Recruiting NCT05692622 - Home-based Complex Intervention for Children With Ataxia Telangiectasia N/A
Recruiting NCT04037189 - Treatment of Leukemia and Lymphoma in Children With Ataxia Telangiectasia
Not yet recruiting NCT04887311 - MBM-01 (Tempol) for the Treatment of Ataxia Telangiectasia Phase 2
Active, not recruiting NCT00951886 - The Validity of Forced Expiratory Maneuvers in Ataxia Telangiectasia Studied Longitudinally N/A
Recruiting NCT03759678 - N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T) Phase 2
Recruiting NCT01052623 - Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT) Phase 4